Author of

• 12791

  +

  P3.19 - Poster Session 3 - Imaging (ID 181)

  • Event: WCLC 2013
  • Type: Poster Session
  • Track: Imaging, Staging & Screening
  • Presentations: 1
  • Moderators:
  • Coordinates: 10/30/2013, 09:30 - 16:30, Exhibit Hall, Ground Level

  • 12810

    +

    P3.19-019 - Evaluation of Erlotinib treatment response in non-small cell lung cancer using EORTC metabolic criteria, PERCIST and anatomic criteria RECIST (ID 3328)

    09:30 - 09:30  |  Author(s): A. Stefano
    • Abstract

    Background
    PET for early prediction of tumor response to Erlotinib in patients with advanced non small cell lung cancer NSCLC has been evaluated. The aim of this prospective study was to compare the early metabolic treatment response using European Organization for Research and Treatment of Cancer (EORTC) 1999 recommendations, PET Response Criteria in Solid Tumors (PERCIST), and the standard treatment response using Response Evaluation Criteria in Solid Tumors (RECIST).

    Methods
    PET was performed before treatment and after 45 days of receiving Erlotinib 150 mgrs daily in advanced NSCLC pts. The hottest lesion in each patient was evaluated according to the EORTC 1999 recommendations, PERCIST and RECIST to assess metabolic and anatomic response. Response classifications were compared statistically using Wilcoxon signed-rank test. Overall survival (OS) and Progression-Free Survival (PFS) time were calculated by the Kaplan-Meier test.

    Results
    14 patients (10 men and 4 women, mean age: 64.1±12.0 years, range 38 to 79 years) were evaluated. Anatomic responses according to RECIST were as follows: 4 Partial Response (PR) and 10 Progressive Disease (PD). Metabolic responses according to EORTC criteria were 5 Partial Metabolic Response (PMR), 5 Stable Metabolic Disease (SMD), and 4 Progressive Metabolic Comparisons of EORTC and RECIST assessment with PERCIST were as follows:

    	PERCIST
    RECIST	PMR	SMD	PMD	Total
    PR	4	0	0	4
    SD	0	0	0	0
    PD	0	6	4	10
    Total	4	6	4	14
    EORTC
    PMR	4	1	0	5
    SMD	0	5	0	5
    PMD	0	0	4	4
    Total	4	6	4	14

    There was a significant difference in the results of response classification between metabolic classifications and RECIST (p<0.04). RECIST and PERCIST (Responders vs. Non-responders) were significant factors associated with DFS ( HR =4.070; 95% CI, 1.383-11.972; p=0.002 for RECIST and HR =0.245; 95% CI, 0.0835-0.722; p=0.001 for PERCIST) and OS ( HR =2.620; 95% CI, 0.8806-7.795; p<0.046 for RECIST and HR =0.3817; 95% CI, 0.1283-1.1356; p=0.046 for PERCIST). EORTC criteria was a significant prognostic factor for predicting DFS ( HR = 0.319; 95% CI, 0.061-1.667; p=0.028) but not for OS (p=0.65).

    Conclusion
    Metabolic and anatomic response were different in NSCLC pts treated with Erlotinib. PERCIST can be considered an appropriate metabolic evaluation method of therapeutic efficacy to discriminate responders from non responders. Mature results will be presented.